Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); Data from Phase 2 “Evidence of Effect” Trial in Claudication Confirm the Rapid Effect of CK-357
Go back to Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); Data from Phase 2 “Evidence of Effect” Trial in Claudication Confirm the Rapid Effect of CK-357| Amgen Inc (NASDAQ: AMGN) | Delayed: 415.21 -2.63 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $417.84 | 52 Week High | $176.85 | |||
| Open | $413.76 | 52 Week Low | $133.64 | |||
| Day High | $416.03 | P/E | 62.53 | |||
| Day Low | $410.50 | EPS | $6.64 | |||
| Volume | 2,036,286 | |||||
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 74.13 +0.68 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $73.45 | 52 Week High | $13.18 | |||
| Open | $72.70 | 52 Week Low | $6.00 | |||
| Day High | $74.26 | P/E | N/A | |||
| Day Low | $72.12 | EPS | $-1.24 | |||
| Volume | 1,756,949 | |||||
